US · Healthcare · Biotechnology
EPS came in at -0.20 against a street estimate of -0.30 — a beat of 33.3%.
Analysts rate Whitehawk Therapeutics, Inc. a buy (6 buy, 3 hold, 0 sell out of 9) with an average price target of $7.71.
| Fund | Stake |
|---|---|
| Yu Fan | 8.53% |
| Longwood Capital Partners LLC | 8.22% |
| Qvt Financial LP | 8.10% |
| Suvretta Capital Management, LLC | 7.54% |
| Orbimed Advisors LLC | 6.90% |
| venBio Select Advisor LLC | 5.00% |
| Siren, L.L.C. | 4.10% |
| KVP Capital Advisors, LP | 3.80% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Whitehawk Therapeutics, Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.